Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicis to restate financial results

This article was originally published in Scrip

Executive Summary

Medicis Pharmaceuticalshas suspended its financial guidance for the rest of the year and has said that its financial statements for the annual, transition and quarterly periods from 2003 will probably need to be restated. The restatement has been caused by necessary modifications in the company's interpretation of the generally accepted accounting principles relating to sales return reserve calculations, Medicis says. Although it said that the restatement was not expected to affect its cash flow or cash balance for any of the affected periods, the company's share price plunged by nearly 16% on September 24th. Sales of Medicis's lead product Solodyn (minocycline HCl) have been hit by the weak US economy and the product will soon face generic competition.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC028010

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel